2022 Disease Nuclear Medicine Radiopharmaceuticals 
Imaging Technology
JUNE 10, 2024
Anderson , PhD, a trailblazer in nuclear medicine, has been named the 2024 recipient of the Georg Charles de Hevesy Nuclear Pioneer Award. The award was announced by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) during its 2024 Annual Meeting, June 8-11 in Toronto.
AuntMinnie
JUNE 9, 2024
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has bestowed its Georg Charles de Hevesy Nuclear Pioneer award on Carolyn Anderson, PhD, of the University of Missouri-Columbia (MU). The award honors those who have made outstanding contributions in the field of nuclear medicine, the SNMMI said.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuntMinnie
AUGUST 12, 2024
SPECT/CT imaging can help manage patients undergoing radiopharmaceutical therapy (RPT) with Pluvicto for advanced prostate cancer, according to a study published August 8 in the Journal of Nuclear Medicine. Yet whether SPECT/CT can be used to determine disease progression or response has yet to be delineated, they noted.
AuntMinnie
MARCH 26, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.
Imaging Technology
OCTOBER 4, 2024
As Theranostics and the use of radiopharmaceutical therapy (RPT) to treat cancer and other diseases have become more prevalent, interest in using dosimetry to personalize RPT treatments has grown. Dosimetry in Radiopharmaceutical Therapy. 2022 Oct;63(10):1467-1474. J Nucl Med. doi: 10.2967/jnumed.121.262305. 121.262305.
AuntMinnie
APRIL 4, 2024
A decade ago, only a few radiopharmaceutical agents were used to help treat cancer patients. He also helped lead the theranostics conference at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 midwinter meeting. However, few freestanding theranostics centers exist today. Hope added.
AuntMinnie
JUNE 20, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.
Expert insights. Personalized for you.
104 
Let's personalize your content